Posted by Michael Wonder on 31 Mar 2021
Amarin receives European Commission approval for Vazkepa to reduce cardiovascular risk
30 March 2021 - Marks first and only European Commission approved treatment to reduce cardiovascular risk in high risk, statin treated adult patients who have elevated triglycerides (≥150 mg/dL) and other risk characteristics as studied in REDUCE-IT.
Amarin Corporation today announced that following a review and approval recommendation by the EMA, the European Commission has approved the marketing authorisation application for Vazkepa (icosapent ethyl) to reduce the risk of cardiovascular events in high-risk, statin treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established cardiovascular disease or diabetes and at least one additional cardiovascular risk factor.
